Today: 1 May 2026
Browse Category

NASDAQ:MRNA 11 November 2025 - 7 January 2026

S&P 500 2026 Forecast: 7,490 Target Meets a Data Test as Earnings Season Nears

S&P 500 2026 Forecast: 7,490 Target Meets a Data Test as Earnings Season Nears

The S&P 500 closed at 6,944.82, up 0.62%, while the Dow hit a record. SanDisk surged over 27% and Western Digital gained 17% after Nvidia’s CES appearance. Labor data including JOLTS and payrolls are due this week, with CPI and JPMorgan Chase earnings set for Jan. 13. A Reuters poll shows most strategists expect a 2026 market correction and S&P 500 at 7,490 by year-end.
7 January 2026
·····
Moderna stock slides premarket after 11% surge on flu vaccine filings — what investors watch next

Moderna stock slides premarket after 11% surge on flu vaccine filings — what investors watch next

Moderna shares fell 1.4% to $35.15 premarket Wednesday after a 10.9% surge Tuesday, following news it filed for approval of its mRNA flu vaccine in the U.S., Europe, Canada, and Australia. The company reported 26.6% relative efficacy for the vaccine in adults 50 and older. Bayer’s Monsanto unit sued Moderna and other COVID-19 vaccine makers Tuesday, alleging mRNA patent infringement.
7 January 2026
··
Dow Jones breaks above 49,000 in record close as chip-led rally rolls on

Dow Jones breaks above 49,000 in record close as chip-led rally rolls on

The Dow Jones closed above 49,000 for the first time Tuesday, ending at 49,462.08, up 1%. Chip and healthcare stocks led gains, with Moderna jumping nearly 11% and the PHLX semiconductor index hitting a record. Data-storage shares surged, while Nvidia and AMD slipped after CES presentations. Investors await Wednesday’s JOLTS and Friday’s U.S. jobs report for rate clues.
6 January 2026
······
Dow nears 50,000 as Nvidia CES remarks ignite SanDisk, Micron surge and lift Wall Street

Dow nears 50,000 as Nvidia CES remarks ignite SanDisk, Micron surge and lift Wall Street

The Dow hit a record high Tuesday, rising 1.02% to 49,476.54 as chip and healthcare shares led gains. SanDisk surged 23% on AI hardware optimism tied to CES, while Johnson Controls fell 7.5% after Nvidia’s chip announcement. Investors monitored U.S. jobs data and Fed signals following gaps caused by last year’s federal shutdown.
6 January 2026
············
Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday

Moderna Stock (MRNA) News: Weekend Pause After Post-Holiday Drop, Analyst Targets, and What to Watch for Monday

Moderna shares fell 4.73% to $31.20 Friday, closing out a volatile holiday week with no major company news or FDA headlines in the past 48 hours. After-hours trading edged lower near $31.10. Barron’s and MarketBeat flagged the stock’s sharp move and heavy trading volume. Analyst commentary focused on technicals and sector positioning rather than new fundamentals.
28 December 2025
··
Moderna Stock (MRNA) Drops in Thin Post-Christmas Trading: Today’s Price Action, Latest News, and Analyst Forecasts

Moderna Stock (MRNA) Drops in Thin Post-Christmas Trading: Today’s Price Action, Latest News, and Analyst Forecasts

Moderna shares fell about 4.4% to $31.31 in early afternoon trading Tuesday, underperforming a steady broader market near record highs. Trading volume was light, typical for the post-holiday period. No single news event drove the decline, with analysts citing thin liquidity and ongoing uncertainty around U.S. vaccine policy and Moderna’s future pipeline.
26 December 2025
··
Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

Moderna Stock (MRNA) Today: Shares Cool Off After a Late-December Spike as Investors Focus on Bird Flu Funding, mNEXSPIKE’s EU Path, and 2026 Growth Targets

Moderna shares fell 7.48% to $32.29 on Dec. 23 after a sharp rally earlier in the week. The drop followed news of up to $54.3 million in CEPI funding for its bird flu vaccine, with a Phase 3 trial set for early 2026. The stock’s volatility contrasted with broader market gains, as investors reacted to recent headlines and year-end trading dynamics.
24 December 2025
··
Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)

Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)

Moderna shares rose about 9% to $33.80 after the company secured up to $54.3 million from CEPI for a Phase 3 trial of its H5 bird flu vaccine. The funding follows a canceled U.S. government contract earlier this year. Meanwhile, U.S. regulators are reviewing possible COVID-19 vaccine safety issues, with conflicting reports on potential FDA warnings.
20 December 2025
·
Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna shares closed at $27.70 on December 5, up 8.7% on volume over 16 million. The rally followed a major French study showing no increase in long-term mortality from mRNA COVID vaccines and a new $1.5 billion credit facility. The stock is still down more than 50% over the past year despite recent gains. Year-to-date performance remains negative at –38.7%.
6 December 2025
··
Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook

Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook

Moderna shares dropped 7% on December 1 after news that the FDA may tighten vaccine approval standards, following an internal memo linking COVID-19 vaccines to pediatric deaths. The stock rebounded to close at $27.70 on December 5, up 8.7% after a large French study reaffirmed the safety of its vaccine. Moderna’s market cap now stands at $10.8 billion, far below its pandemic peak.
6 December 2025
Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna (MRNA) Stock Jumps on New Vaccine Safety Data – Latest News, Forecast & Analysis for December 5, 2025

Moderna shares jumped nearly 9% on December 5, closing at about $27–28 after a large French study backed the long-term safety and effectiveness of mRNA COVID vaccines. The stock remains down roughly 34% year-to-date and trades around 40% below its 52-week high. Investors also weighed a new $1.5 billion loan deal and updated guidance on future growth.
5 December 2025
··
Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna (MRNA) Stock Today, November 23, 2025: Short-Seller Pressure, $1.5 Billion Loan and mRNA Pipeline Reset

Moderna closed at $23.72 on Friday, near its 52-week low and down 38% over the past year. The company is now the most shorted stock in the S&P 500, with short interest near 18% as COVID vaccine sales collapse. Moderna has announced a new three-year strategy, $1.5 billion in new debt, and pipeline cuts while focusing on mRNA drugs for cancer and respiratory disease.
23 November 2025
·
Moderna (MRNA) today — Nov. 12, 2025: Special shareholder vote on option exchange, fresh institutional filings, and live stock action

Moderna (MRNA) today — Nov. 12, 2025: Special shareholder vote on option exchange, fresh institutional filings, and live stock action

Moderna shareholders are voting today on a one-time stock option exchange for non-executive employees, which could cut outstanding options by about 3.44 million shares. BNY Mellon reduced its MRNA stake by 16% last quarter, while Campbell & CO opened a new position. MRNA shares are trading higher intraday as investors await the vote and assess recent earnings.
12 November 2025
·
Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna (MRNA) News Today—November 11, 2025: UBS Sees 2026 Upside, Redburn Cuts PT to $36, Bernstein Stays Market Perform After Cost Cuts

Moderna shares rose mid-session Tuesday after UBS cited 2026 upside tied to cost cuts and pipeline progress. Redburn Atlantic lowered its price target to $36, while Bernstein reiterated a $25 target and neutral view, highlighting the need for further expense reductions. The moves follow last week’s Q3 report, which showed a narrower loss and tighter 2025 guidance.
11 November 2025
··
1 2 3

Stock Market Today

  • Verisk Analytics (VRSK) Valuation Review Post Earnings Beat and Capital Returns
    May 1, 2026, 4:17 AM EDT. Verisk Analytics (VRSK) reported stronger-than-expected Q1 2026 results, reaffirmed full-year guidance, and announced a $1.5 billion share buyback along with a dividend increase. Despite these positives, the stock trades about 24% below a fair value estimate of $221.53, implying it is 16.7% undervalued based on a narrative model factoring growth and margins. The current price of $184.49 also reflects a price-to-earnings (P/E) ratio of 26.6x, below peer average but above the U.S. Professional Services sector, signaling mixed valuation signals. Risks include potential cuts in client spending and AI-driven pricing pressures. Investors weigh recent modest growth against valuation gaps amid evolving market sentiment.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026
LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 4:22 AM EDT Verisk Analytics (VRSK) Valuation Review Post Earnings Beat and Capital Returns May 1, 2026, 4:17 AM EDT. Verisk Analytics (VRSK) reported stronger-than-expected Q1 2026 results, reaffirmed full-year guidance, and announced a $1.5 billion share buyback along with a dividend increase. Despite these positives, the stock trades about 24% below a fair value estimate of $221.53, implying it is 16.7% undervalued based on a narrative model factoring growth and margins. The current price of $184.49 also reflects a price-to-earnings (P/E) ratio of 26.6x, below peer average
Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Go toTop